Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 12/20 | 0.44 |
| ▸ | PPARA | Q07869 | 11/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530493 | 0.88 | RAB9A (0.53) | KDM4EHRH3PPARGPPARAPPARD | |
| SCHEMBL5385072 | 0.87 | KDM4E (0.50) | KDM4EHRH3PPARGPPARAPPARD | |
| SCHEMBL820945 | 0.85 | SMN1; SMN2 (0.51) | KDM4EHRH3PPARGPPARAPPARD | |
| SCHEMBL979145 | 0.85 | KDM4E (0.65) | KDM4EHRH3PPARGPPARAPPARD | |
| SCHEMBL7722459 | 0.84 | HRH3 (0.46) | KDM4EHRH3PPARGPPARAPPARD | |
| SCHEMBL1981068 | 0.83 | PPARG (0.54) | KDM4EHRH3PPARGPPARAPPARD | |
| SCHEMBL1436227 | 0.83 | HSD17B10 (0.54) | KDM4EPPARGPPARANPC1RAB9A | |
| SCHEMBL1436051 | 0.83 | PPARA (0.51) | KDM4EHRH3PPARGPPARAPPARD | |
| SCHEMBL4888378 | 0.83 | RAB9A (0.62) | KDM4EHRH3PPARGPPARAPPARD | |
| SCHEMBL4890697 | 0.82 | PPARA (0.54) | KDM4EPPARGPPARANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1093124-C | Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' | GLAXO GROUP LTD (GB) | 2002-10-23 | — | — | CN | disclosed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| CN-1218460-A | Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' | GLAXO GROUP LTD (GB) | 1999-06-02 | — | — | CN | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |